Bridging Nations, Diverging Views: Exploring the Global Landscape of Indirect Treatment Comparisons Acceptance by Health Technology Assessment Bodies
Speaker(s)
Moderator: Chris G Cameron, MSc, PhD, EVERSANA, Sydney, NS, Canada
Panelists: Stefan Lange, MD, Dierks+Company, Berlin, BE, Germany; Olivia Wu, PhD, Health Economics and Health Technology Assessment (HEHTA) and NIHR Evidence Synthesis Group at the Complex Reviews Synthesis Unit, University of Glasgow, Glasgow, UK; Nicholas Adlard, MA MSc MBA, International HEOR, Novartis Pharmaceuticals UK Ltd, Busserach, SO, Switzerland
ISSUE:
In the absence of head-to-head randomized controlled trials, indirect treatment comparisons (ITCs) can be used to derive comparative effectiveness between therapies. However, there is significant variation in global health technology assessment (HTA) agencies’ acceptance of ITC methodologies, resulting in inconsistent decisions on drug reimbursements, and hindering timely patient access. As the global landscape of the role of ITCs in HTA submissions continues to evolve, particularly with EU’s joint clinical assessment (JCA), it is critical to discuss the key barriers to ITC acceptance and to identify appropriate methodological approaches to increase the value and transparency of ITCs for decision-making.OVERVIEW:
This panel seeks to dissect the challenges and disparate viewpoints surrounding the utilization of ITCs in HTA submissions and their acceptance by global HTA agencies. Moderated by Dr. Chris Cameron, this panel will delve into the key barriers to acceptance of ITCs, potential strategies to consider in addressing these concerns, and emerging trends shaping the acceptance landscape. The panel discussion will be 50 minutes in length, plus 10 minutes for audience questions. Key questions include:- What do you see as the key barriers to acceptance of ITCs by HTA agencies?
- What do you believe specifically needs to be done by industry sponsors to overcome these barriers when submitting ITCs to HTA agencies?
- How will EU JCA improve the consistency and acceptance of ITCs used in HTA submissions across Europe?
Code
313
Topic
Health Technology Assessment